<SEC-DOCUMENT>0001104659-19-041172.txt : 20190722
<SEC-HEADER>0001104659-19-041172.hdr.sgml : 20190722
<ACCEPTANCE-DATETIME>20190722080831
ACCESSION NUMBER:		0001104659-19-041172
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190722
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190722
DATE AS OF CHANGE:		20190722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		19964514

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a19-13022_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Current Report</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> July&nbsp;22, 2019</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">England   and Wales</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-37368</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not   Applicable</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction of<br>   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">60 Jubilee Avenue, Milton Park</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Abingdon, Oxfordshire OX14 4RX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices, including zip code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44) 1235 430000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .3in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt .3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .3in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .3in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt .3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .3in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt .3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (</font>&#167;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company </font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. </font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of the Act:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="44%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Title&nbsp;of&nbsp;each&nbsp;class</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Trading&nbsp;Symbol</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which<br>   &nbsp;registered</font></b></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">American Depositary   Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAP</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Nasdaq Global   Select Market</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\C905653\19-13022-1\task9429513\13022-1-ba.htm',USER='C905653',CD='Jul 19 08:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Events.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">On July&nbsp;22, 2019, Adaptimmune Therapeutics plc </font>issued a press release announcing that it has initiated a radiation sub-study of its ADP-A2M4 trial in collaboration with the University of Texas MD Anderson Cancer Center in Houston, TX. The press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Statements and Exhibits.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp; Exhibits.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="85%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:85.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a19-13022_1ex99d1.htm#Exhibit99_1_013714" title="Click to goto ">Press   release dated July&nbsp;22, 2019.</a></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_013510_7528"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\jms\C905653\19-13022-1\task9429513\13022-1-ba.htm',USER='C905653',CD='Jul 19 08:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAPTIMMUNE   THERAPEUTICS PLC</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: July&nbsp;22,   2019</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_013554_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\jms\C905653\19-13022-1\task9429513\13022-1-ba.htm',USER='C905653',CD='Jul 19 08:23 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a19-13022_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1<a name="Exhibit99_1_013714"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in .2in .0001pt 0in;text-align:right;"><font size="2" face="Times New Roman"><img width="281" height="62" src="g130221mmi001.jpg"></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">- </font></b>Compelling responses previously reported with ADP-A2M4 in sarcoma -</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">- Use of low-dose radiation intended to enhance antitumor activity -</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PHILADELPHIA and OXFORDSHIRE, United Kingdom, July&nbsp;22, 2019 &#151; Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, </font>has initiated a radiation sub-study of its ADP-A2M4 trial in collaboration with the University of Texas MD Anderson Cancer Center in Houston, TX. Published data indicate that low-dose radiation has the potential to enhance T-cell responses in the context of solid tumors.(1)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We have seen compelling data in sarcoma with ADP-A2M4 SPEAR T-cells and will initiate our SPEARHEAD-1 trial for sarcoma patients later this year. In addition, we are eager to increase the depth and durability of the antitumor activity that we have observed in other solid tumors with ADP-A2M4,&#148; said Rafael Amado, Adaptimmune&#146;s President of R&amp;D. &#147;There is emerging data showing that low-dose radiation could enhance T-cell tumor trafficking and responses. We are looking forward to the results of this radiation sub-study with ADP-A2M4.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The radiation sub-study is planned to enroll 10 patients across multiple solid tumor indications. Patients will receive low-dose radiation in up to 5&nbsp;lesions prior to treatment with ADP-A2M4, at target doses of 1 to 10&nbsp;billion SPEAR T-cells. The lymphodepletion regimen will be fludarabine (30&nbsp;mg/m</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day) for 4 days and cyclophosphamide (600&nbsp;mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day) for 3 days.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune and the MD Anderson Cancer Center </font>have a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients. The Company&#146;s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T</font>-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form&nbsp;10-Q filed with the Securities and Exchange Commission (SEC) on May&nbsp;6,&nbsp;2019, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp; *Barsoumian, 2018; DeSelm, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="PB_1_013912_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C605009\19-13022-1\task9429719\13022-1-mm.htm',USER='C605009',CD='Jul 19 14:18 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media Relations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">S&#233;bastien Desprez &#151; VP, Communications and Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 1235 430 583</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +44 7718 453 176</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sebastien.Desprez@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Relations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli P. Miller, Ph.D. &#151; Senior Director,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +1 215 825 9310</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +1 215 460 8920</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli.Miller@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_013941_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C605009\19-13022-1\task9429719\13022-1-mm.htm',USER='C605009',CD='Jul 19 14:18 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g130221mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g130221mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  ^ 1D# 2(  A$! Q$!_\0
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MY29 Z_0C-<#H/A?0[_7YKB768=6F^:1H=N.2>IYYQ7H,44<$2Q0HJ1H,*JC
M JX7^1P8Z4&TKMRZM_HB.]NX[&SFN9CB.)"[?A7#>'M9U*#7+>?5)7^RZL&\
ME68[4.>,#MZ?B*U?&$KZC=6.@6Y.^[</,1_#&/\ /Z5:\5:*+OPYY=HFV:S
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?.(*YB"J<G*\,<^F<X]JU:0 #H /I2T(B;4I72L?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
